Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization

doi:10.1055/s-0040-1714060

Observational Study

. 2020 Sep;37(11):1110-1114.

doi: 10.1055/s-0040-1714060. Epub 2020 Jul 3.

Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization

Michael J Fassett¹, Lawrence D Lurvey², Lyn Yasumura³, Marielle Nguyen⁴, Joseph J Colli⁵, Marianna Volodarskiy⁶, Jonathan C Gullett⁷, David Braun⁸, Alex Fong⁹, Neha Trivedi¹⁰, Katia Bruxvoort⁸, Vicki Chiu⁸, Darios Getahun^{8

11}

Affiliations

¹ Department of Maternal-Fetal Medicine, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California.
² Southern California Permanente Medical Group, Pasadena, California.
³ Department of Obstetrics and Gynecology, Kaiser Permanente Baldwin Park Medical Center, Baldwin Park, California.
⁴ Department of Neonatal Medicine, Kaiser Permanente Anaheim Medical Center, Anaheim, California.
⁵ Department of Neonatal Medicine, Kaiser Permanente South Bay Medical Center, Los Angeles, California.
⁶ Kaiser Foundation Hospitals, Pasadena, California.
⁷ Southern California Permanente Medical Group Regional Reference Laboratories, North Hollywood, California.
⁸ Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
⁹ Department of Maternal-Fetal Medicine, Kaiser Permanente Irvine Medical Center, Irvine, California.
¹⁰ Department of Maternal-Fetal Medicine, Kaiser Permanente San Diego Medical Center, San Diego, California.
¹¹ Department of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.

PMID: 32620022
PMCID: PMC7516390
DOI: 10.1055/s-0040-1714060

Observational Study

Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization

Michael J Fassett et al. Am J Perinatol. 2020 Sep.

. 2020 Sep;37(11):1110-1114.

doi: 10.1055/s-0040-1714060. Epub 2020 Jul 3.

Authors

Affiliations

¹ Department of Maternal-Fetal Medicine, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California.
² Southern California Permanente Medical Group, Pasadena, California.
³ Department of Obstetrics and Gynecology, Kaiser Permanente Baldwin Park Medical Center, Baldwin Park, California.
⁴ Department of Neonatal Medicine, Kaiser Permanente Anaheim Medical Center, Anaheim, California.
⁵ Department of Neonatal Medicine, Kaiser Permanente South Bay Medical Center, Los Angeles, California.
⁶ Kaiser Foundation Hospitals, Pasadena, California.
⁷ Southern California Permanente Medical Group Regional Reference Laboratories, North Hollywood, California.
⁸ Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
⁹ Department of Maternal-Fetal Medicine, Kaiser Permanente Irvine Medical Center, Irvine, California.
¹⁰ Department of Maternal-Fetal Medicine, Kaiser Permanente San Diego Medical Center, San Diego, California.
¹¹ Department of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.

PMID: 32620022
PMCID: PMC7516390
DOI: 10.1055/s-0040-1714060

Abstract

Objective: The coronavirus disease 2019 (COVID-19) pandemic has created a need for data regarding the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnant women. After implementing universal screening for COVID-19 in women admitted for delivery, we sought to describe the characteristics of COVID-19 in this large cohort of women.

Study design: An observational study of women admitted to labor and delivery units in Kaiser Permanente Southern California (KPSC) hospitals between April 6 and May 11, 2020 who were universally offered testing for SARS-CoV-2 infection (n = 3,963). Hospital inpatient and outpatient physician encounter, and laboratory records were used to ascertain universal testing levels, test results, and medical and obstetrical histories. The prevalence of SARS-CoV-2 infection was estimated from the number of women who tested positive during labor per 100 women delivered.

Results: Of women delivered during the study period, 3,923 (99.0%) underwent SARS-CoV-2 testing. A total of 17 (0.43%; 95% confidence interval: 0.23-0.63%) women tested positive, and none of them were symptomatic on admission. There was no difference in terms of characteristics between SARS-CoV-2 positive and negative tested women. One woman developed a headache attributed to COVID-19 3 days postpartum. No neonates had a positive test at 24 hours of life.

Conclusion: The findings suggest that in pregnant women admitted for delivery between April 6 and May 11, 2020 in this large integrated health care system in Southern California, prevalence of SARS-CoV-2 test positive was very low and all patients were asymptomatic on admission.

Key points: · The prevalence of SARS-CoV-2 infection in a large diverse cohort of term pregnant women was 0.43%.. · 99% of women accepted SARS-CoV-2 screening on admission to labor and delivery.. · All women with positive test results were asymptomatic at the time of testing..

PubMed Disclaimer

Conflict of interest statement

None declared.

Cited by

Maternal COVID-19 infection and associated factors: A cross-sectional study.
Lubeya MK, Kabwe JC, Mukosha M, Phiri SN, Phiri CC, Muyovwe M, Price JT, Jacobs C, Kaonga P. Lubeya MK, et al. PLoS One. 2023 Mar 15;18(3):e0281435. doi: 10.1371/journal.pone.0281435. eCollection 2023. PLoS One. 2023. PMID: 36920919 Free PMC article.
Influence of the COVID-19 pandemic on labor and childbirth care practices in Brazil: a cross-sectional study.
de Menezes FR, da Silva TPR, Felisbino-Mendes MS, Dos Santos LC, de Almeida Pereira Canastra MA, Filipe MML, Abreu MNS, Lana FCF, Ferreira FM, Moreira AD, Martins EF, Matozinhos FP. de Menezes FR, et al. BMC Pregnancy Childbirth. 2023 Feb 3;23(1):91. doi: 10.1186/s12884-023-05358-2. BMC Pregnancy Childbirth. 2023. PMID: 36732728 Free PMC article.
Association of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection With Maternal Mortality and Neonatal Birth Outcomes in Botswana by Human Immunodeficiency Virus Status.
Jackson-Gibson M, Diseko M, Caniglia EC, Mayondi GK, Mabuta J, Luckett R, Moyo S, Lawrence P, Matshaba M, Mosepele M, Mmalane M, Banga J, Lockman S, Makhema J, Zash R, Shapiro RL. Jackson-Gibson M, et al. Obstet Gynecol. 2023 Jan 1;141(1):135-143. doi: 10.1097/AOG.0000000000005020. Epub 2022 Nov 30. Obstet Gynecol. 2023. PMID: 36701614 Free PMC article.
Monitoring SARS-CoV-2 seroprevalence over time among pregnant women admitted to delivery units: Suitability for surveillance.
Miyadahira MY, Brizot ML, Alexander N, Cerdeira Sabino E, Campos de Oliveira da Silva L, Hoshida MS, da Silva Sousa Oliveira AM, Silva Farche AC, Pulcineli Vieira Francisco R, Mayaud P. Miyadahira MY, et al. PLoS One. 2023 Jan 5;18(1):e0280109. doi: 10.1371/journal.pone.0280109. eCollection 2023. PLoS One. 2023. PMID: 36603011 Free PMC article.
Effect of asymptomatic COVID-19 infection on the placenta in the third trimester of pregnancy: A prospective case-control study.
Şahin O, Altay AY, Aydın E, Bağcı H, Yalçın Ö. Şahin O, et al. Turk J Obstet Gynecol. 2022 Sep 23;19(3):178-186. doi: 10.4274/tjod.galenos.2022.94984. Turk J Obstet Gynecol. 2022. PMID: 36149229 Free PMC article.

See all "Cited by" articles

References

1. https://s3.amazonaws.com/cdn.smfm.org/media/2305/joint-statement-recent-... https://s3.amazonaws.com/cdn.smfm.org/media/2305/joint-statement-recent-...
1. Breslin N, Baptiste C, Gyamfi-Bannerman C. COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020;2(02):100118. - PMC - PubMed
1. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med. 2020;382(22):2163–2164. - PMC - PubMed
1. Abbott RealTime SARS-CoV-2 assay [package insert], Des Plaines, IL. Abbott MolecularAvailable at:https://www.molecular.abbott/us/en/products/infectious-disease/RealTime-.... Accessed 2020
1. Cobas® SARS CoV-2 assay [package insert], Indianapolis, IN. Roche Diagnostics; Available at:https://www.roche.com/media/releases/med-cor-2020-03-13.htm. Accessed 2020

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

Funding This study was supported by Kaiser Permanente Direct Community Benefit Funds.

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] https://s3.amazonaws.com/cdn.smfm.org/media/2305/joint-statement-recent-... https://s3.amazonaws.com/cdn.smfm.org/media/2305/joint-statement-recent-...

[2] https://s3.amazonaws.com/cdn.smfm.org/media/2305/joint-statement-recent-... https://s3.amazonaws.com/cdn.smfm.org/media/2305/joint-statement-recent-...

[3] Breslin N, Baptiste C, Gyamfi-Bannerman C. COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020;2(02):100118. - PMC - PubMed

[4] Breslin N, Baptiste C, Gyamfi-Bannerman C. COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020;2(02):100118. - PMC - PubMed

[5] Sutton D, Fuchs K, D'Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med. 2020;382(22):2163–2164. - PMC - PubMed

[6] Sutton D, Fuchs K, D'Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. N Engl J Med. 2020;382(22):2163–2164. - PMC - PubMed

[7] Abbott RealTime SARS-CoV-2 assay [package insert], Des Plaines, IL. Abbott MolecularAvailable at:https://www.molecular.abbott/us/en/products/infectious-disease/RealTime-.... Accessed 2020

[8] Abbott RealTime SARS-CoV-2 assay [package insert], Des Plaines, IL. Abbott MolecularAvailable at:https://www.molecular.abbott/us/en/products/infectious-disease/RealTime-.... Accessed 2020

[9] Cobas® SARS CoV-2 assay [package insert], Indianapolis, IN. Roche Diagnostics; Available at:https://www.roche.com/media/releases/med-cor-2020-03-13.htm. Accessed 2020

[10] Cobas® SARS CoV-2 assay [package insert], Indianapolis, IN. Roche Diagnostics; Available at:https://www.roche.com/media/releases/med-cor-2020-03-13.htm. Accessed 2020

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization

Affiliations

Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous